Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Approaches for Disorders of Gut-Brain Interaction Other Than Medication.

Gastroenterology & hepatology·2026
Same authorSame journal

Update on the Management of Pregnant Patients With Inflammatory Bowel Disease.

Gastroenterology & hepatology·2026
Same author

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

The American journal of gastroenterology·2026
Same author

Nutritional Management of Adult Patients Who Have Crohn's Disease.

Gastroenterology & hepatology·2026
Same author

The Evolving Concept of a Therapeutic Window of Opportunity for Crohn's Disease.

Gastroenterology & hepatology·2026
Same author

Spotlight on the Surveillance of Pouches.

Gastroenterology & hepatology·2026
Same journal

Management of Granulomatous Hepatitis.

Gastroenterology & hepatology·2026
Same journal

Update on Pregnancy in Inflammatory Bowel Disease.

Gastroenterology & hepatology·2026
Same journal

Strategies for Improving Hepatocellular Carcinoma Surveillance Rates.

Gastroenterology & hepatology·2026
Same journal

Managing the Diagnostic and Therapeutic Challenges of Irritable Bowel Syndrome.

Gastroenterology & hepatology·2026
Same journal

Raising the Bar on Risk Reduction in Post-ERCP Pancreatitis Prevention.

Gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

5-ASA Dose-Response: Maximizing Efficacy and Adherence.

Seymour Katz1, Gary R Lichtenstein, Michael A Safdi

  • 1Seymour Katz, MD Clinical Professor, Albert Einstein College of Medicine, Bronx, New York.

Gastroenterology & Hepatology
|June 23, 2010
PubMed
Summary
This summary is machine-generated.

Higher doses of mesalamine (5-aminosalicylic acid; 5-ASA) are more effective for treating moderate ulcerative colitis. Optimal dosing improves symptom resolution, maintains remission, and enhances quality of life.

More Related Videos

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Experiment Videos

Last Updated: Jun 12, 2026

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Mesalamine (5-aminosalicylic acid; 5-ASA) is a primary treatment for mild-to-moderate ulcerative colitis (UC).
  • Current guidelines recommend combined oral and rectal 5-ASA for optimal UC management.
  • Challenges include high pill burden for oral formulations and low adherence for rectal therapies.

Purpose of the Study:

  • To evaluate the efficacy of different 5-ASA dosage regimens in UC patients.
  • To assess the impact of 5-ASA therapy on symptom resolution, remission maintenance, and quality of life.
  • To identify optimal dosing strategies for moderate UC.

Main Methods:

  • Review of clinical trial data, including the ASCEND I, II, and III trials.
  • Analysis of patient outcomes based on varying 5-ASA doses (4.8 g/day vs. 2.4 g/day).
  • Consideration of patient subgroups, including those with moderate disease, prior steroid use, and polypharmacy.

Main Results:

  • Doses of 4.8 g/day of 5-ASA demonstrated superior efficacy compared to 2.4 g/day in moderate UC.
  • Higher doses were particularly beneficial for patients with moderate disease, previous steroid use, and multiple medications.
  • Effective 5-ASA therapy is linked to improved quality of life and reduced need for colectomy.

Conclusions:

  • Higher daily doses of mesalamine (4.8 g/day) are more effective for managing moderate ulcerative colitis.
  • Optimizing 5-ASA dosage can lead to better symptom control, sustained remission, and improved patient quality of life.
  • Effective long-term 5-ASA therapy may help avoid more toxic treatments and reduce colectomy risk.